Jagsonpal Pharmaceuticals Ltd P/E Ratio

The P/E Ratio of Jagsonpal Pharmaceuticals Ltd is 45 as of 25 Jul 9.00 AM .a1#The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 9.6 on March 2019 to 28.4 on March 2023 . This represents a CAGR of 24.23% over 5 years. a1#The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 381.95 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.3 in 5 years. This represents a CAGR of -0.72%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.5. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 68.9 crore on March 2019 to ₹ 759.48 crore on March 2023 . This represents a CAGR of 61.61% over 5 years. a1#The Revenue of Jagsonpal Pharmaceuticals Ltd changed from ₹ 60.91 crore to ₹ 45.97 crore over 8 quarters. This represents a CAGR of -13.13% a1#The EBITDA of Jagsonpal Pharmaceuticals Ltd changed from ₹ 4.03 crore to ₹ 5.16 crore over 8 quarters. This represents a CAGR of 13.15% a1#The Net Pr of Jagsonpal Pharmaceuticals Ltd changed from ₹ 2.92 crore to ₹ 3.55 crore over 8 quarters. This represents a CAGR of 10.26% a1#The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 9.07 % on March 2019 to 49.03 % on March 2023 . This represents a CAGR of 40.14% over 5 years. a1#

Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company. The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future. It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia. In the fiscal 2001, the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity. The new manufacturing facility at Pantnagar, Uttarakhand started production in April 2009. The Company launched two brands, Divatrone and ProRetro in the product market segment, Dydrogesterone, which was earlier dominated by a global pharma Company in August, 2021.